News | July 29, 2009

Multi-Lumen Balloon Takes Center Stage at SenoRx AAPM Booth

July 29, 2009 - SenoRx is featuring the Contura Multi-Lumen Balloon (MLB) Catheter for delivering brachytherapy to the surgical margins following lumpectomy for breast cancer in booth 762 at the AAPM 51st Annual Meeting that is taking place in Anaheim, Calif., from July 26-29. SenoRx representatives are demonstrating how Contura is a leader in MLB breast brachytherapy. The Optimal Design enables improved dosimetric coverage of targeted tissue while minimizing the dose to healthy tissue and lungs. Built-in vacuum ports help to aspirate seroma or trapped air providing uniform balloon cavity adherence.
Contura’s polyurethane construction provides balloon symmetry. With its dose-shaping balloon design, physicians are able to treat women who are normally not candidates for APBI with single-lumen balloon catheters. Some patients who are candidates for balloon therapy are currently excluded because of the location of the lesion and their breast size. Contura's advanced multi-lumen design may address this issue for certain patients.
As a result, more women can benefit from five-day brachytherapy.
SenoRx offers several alternatives to get you up to speed on 3D CT based planning using Contura MLB.

For more information: www.senorx.com

Related Content

​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
Intraoperative Radiotherapy Provides Lifetime Cost Savings, Health Benefits for Early-Stage Breast Cancer Treatment
News | Brachytherapy Systems, Women's Healthcare | December 19, 2017
iCAD Inc. announced the results of a landmark study that showed the benefits of adjunct intraoperative radiation...
Cleveland Clinic Leads Development of New Guidelines for Radiation in Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 31, 2017
October 31, 2017 — Cleveland Clinic researcher Chirag Shah, M.D., recently led the development of updated guidelines
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
Pelvic Radiation Confirmed as Standard of Care for High-Risk, Early-Stage Endometrial Cancer
News | Brachytherapy Systems, Women's Healthcare | September 28, 2017
In a new phase III trial report, recurrence-free and overall survival rates for women with stage I-II high-risk...
China FDA Approves Xoft Axxent Balloon Applicators for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | August 30, 2017
iCAD Inc. announced that the company’s Xoft Axxent balloon applicators have received approval from the China Food...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Australia's Monash Cancer Centre Treats First Early-Stage Breast Cancer Patient With Xoft System
News | Brachytherapy Systems, Women's Healthcare | May 01, 2017
iCAD Inc. announced the first early-stage breast cancer patient was treated in Australia with intraoperative radiation...
New Clinical Data on Xoft System Presented at American Brachytherapy Society Annual Meeting
News | Brachytherapy Systems, Women's Healthcare | April 20, 2017
iCAD Inc. announced that updated clinical data on the use of intraoperative radiation therapy (IORT) using the Xoft...
Concure Oncology, Breast Microseed Treatment, one day, low-dose rate brachytherapy, LDR
Technology | Brachytherapy Systems, Women's Healthcare | May 12, 2016
Concure Oncology/Breast Microseed Inc. announced the launch of its one-time, one-hour radiation treatment option for...
Overlay Init